ThromboGenics Licenses Innovative Technology from Eleven Biotherapeutics to Develop Novel Drugs for the Treatment of Diabetic Eye Diseases
LEUVEN, Belgium, May 28, 2013 /PRNewswire/ –
ThromboGenics NV (Euronext Brussels: THR) a biopharmaceutical company focused on
developing and commercializing innovative ophthalmic medicines, announces that it has
commenced research and development of innovative protein therapeutics to address a novel
ThromboGenics-identified biologic target implicated in a range of diabetic eye diseases
such as diabetic macular edema (DME).
ThromboGenics will utilize Eleven Biotherapeutics’ proprietary AMP-Rx protein design
technology to create a novel therapeutic of ThromboGenics’ selection optimized for
improved pharmaceutical characteristics and therapeutic benefits.
ThromboGenics will have the exclusive license to all future developments and
commercialization of this novel protein. In exchange, Eleven Biotherapeutics will receive
an undisclosed upfront payment, and is eligible to receive undisclosed development,
regulatory and sales milestone payments as well as royalties on potential future sales
commensurate with industry standards.
Dr Patrik De Haes, CEO of ThromboGenics, said: “This is an important step forward as
we continue to build our ophthalmology franchise following the recent introduction of
JETREA(R) for the treatment of symptomatic vitreomacular adhesion (VMA)/ vitreomacular
traction (VMT) in the US and Europe. We are pleased to have signed this agreement with
Eleven Biotherapeutics and we are confident that by utilizing their unique ability to
design and optimize protein therapeutics we will generate an innovative protein
therapeutic to address a novel target that we have identified. Our research suggests that
protein therapeutics directed at this target could be used to treat a broad range of
diabetic eye diseases including DME”.
“Eleven’s novel approach to designing protein therapeutics for ocular diseases, which
has been demonstrated with EBI-005, our lead product candidate in Phase 1b clinical
development for dry eye disease, will be applied to discover and optimize novel modulators
of this evolving pathway which is central to ophthalmic disease,” said Abbie Celniker,
President and CEO of Eleven Biotherapeutics. “This collaboration validates Eleven’s unique
approach to rational protein engineering through novel structures, enhanced biophysical
properties, and more effective targeting in disease pathways.”
ThromboGenics is an integrated biopharmaceutical company focused on developing and
commercializing innovative ophthalmic and oncology medicines. The Company’s lead product,
JETREA(R)(ocriplasmin), has been approved by the US FDA for the treatment of symptomatic
VMA and was launched in January 2013.
ThromboGenics signed a strategic partnership with Alcon (Novartis) for the
commercialization of JETREA(R) outside the United States. Under this agreement,
ThromboGenics could receive up to a total of EUR375 million in up-front and milestone
payments. It will receive significant royalties from Alcon’s net sales of JETREA(R).
ThromboGenics and Alcon intend to share the costs equally of developing JETREA(R) for a
number of new vitreoretinal indications.
In Europe, JETREA(R) is approved for the treatment of vitreomacular traction (VMT),
including when associated with macular hole of diameter less than or equal to 400 microns.
Alcon has launched JETREA(R) in the UK and Germany.
ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), also
referred to as TB-403, for the treatment of ophthalmic and oncology indications.
ThromboGenics is headquartered in Leuven, Belgium, and has-offices in Iselin, NJ (US)
and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under
the symbol THR. More information is available at http://www.thrombogenics.com.
About Eleven Biotherapeutics
Eleven Biotherapeutics creates novel and differentiated biotherapeutics:
first-of-a-kind protein-based drugs with significantly improved physical, pharmaceutical,
and therapeutic benefits. The company’s AMP-Rx(TM) product engine brings capabilities
beyond conventional approaches for making protein therapeutics, opening up new territory
for the products to have novel structures, enhanced biophysical properties, and more
effective targeting in disease pathways. Eleven’s success is built on designing proteins
‘fit for purpose’ that are rationally designed to have ideal therapeutic characteristics
and result in best-in-class biotherapeutic products for a wide range of diseases. The
Cambridge, Mass.-based company was founded in 2010 by life science investors Flagship
Ventures and Third Rock Ventures and world-renowned scientific experts. For more
information, please visit http://www.elevenbio.com.
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such
forward-looking statements are based on current expectations, and, accordingly, entail and
are influenced by various risks and uncertainties. The Company therefore cannot provide
any assurance that such forward-looking statements will materialize and does not assume an
obligation to update or revise any forward-looking statement, whether as a result of new
information, future events or any other reason. Additional information concerning risks
and uncertainties affecting the business and other factors that could cause actual results
to differ materially from any forward-looking statement is contained in the Company’s
This press release does not constitute an offer or invitation for the sale or purchase
of securities or assets of ThromboGenics in any jurisdiction. No securities of
ThromboGenics may be offered or sold within the United States without registration under
the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom,
and in accordance with any applicable U.S. state securities laws.
For further information please contact:
Thrombogenics Wouter Piepers, Global Head of Corporate Communications +32-16-75-13-10 / +32-478-33-56-32 Wouter.firstname.lastname@example.org Dr. Patrik De Haes, CEO +32-16-75-13-10 Patrik.email@example.com Chris Buyse, CFO +32-16-75-13-10 Chris.firstname.lastname@example.org Citigate Dewe Rogerson David Dible/ Nina Enegren/ Sita Shah Tel: +44-20-7638-9571 email@example.com The Trout Group (US investor relations) Todd James/ Simon Harnest Tel: +1-646-378-2926 firstname.lastname@example.org